Loading...
•
Mar 31, 2023
Vericel Q1 2023 Earnings Report
Reported record quarterly MACI and total revenue, driven by strong MACI revenue growth, and increased full-year revenue guidance.
Key Takeaways
Vericel Corporation reported a strong start to 2023 with record first-quarter total revenue of $41 million, driven by a 32% increase in MACI revenue to $34.2 million. The company raised its full-year 2023 revenue guidance to $184-$192 million. They also reported a net loss of $7.5 million, or $0.16 per diluted share, and a non-GAAP adjusted EBITDA of $1.7 million.
Record first quarter total revenue of $41 million.
MACI revenue increased 32% to $34.2 million.
Full-year 2023 revenue guidance raised to $184-$192 million.
Highest number of surgeons taking MACI biopsies and second highest number of MACI biopsies in a quarter since launch.
Revenue by Segment
Forward Guidance
Vericel expects total net revenue for 2023 to be in the range of $184 to $192 million and maintains profitability guidance of gross margin in the high-60% range and adjusted EBITDA margin in the mid-teens % range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...